This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antares Pharma Inc (ATRS)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -35.15M -20.51M -11.43M -4.39M
Operating Gains/Losses 39.98K 0.00 119.43K -30.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -2.48M 1.20M 310.81K -1.30M
(Increase) Decrease in Inventories -2.95M -5.46M -118.36K -629.51K
(Increase) Decrease In Other Current Assets -1.54M 381.79K 444.28K 0.00
(Decrease) Increase In Payables 2.69M 2.53M 724.80K 365.52K
(Decrease) Increase In Other Current Liabilities 221.09K 2.53M 687.30K 406.82K
(Increase) Decrease In Other Working Capital 6.03M 2.37M -3.36M 1.76M
Other Non-Cash Items 6.17M 2.44M 2.03M 1.87M
Net Cash From Continuing Operations -26.33M -14.97M -10.47M -1.93M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -26.33M -14.97M -10.47M -1.93M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 30.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -5.65M -3.16M -3.50M -581.80K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 18.35M -293.12K -21.67M -15.61M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 3.11M 2.33M 64.91M 27.30M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -154.40K -104.33K -28.92K -233.29K
Net Cash From Financing Activities 2.95M 2.22M 64.88M 27.07M
Effect of Exchange Rate Changes -2.65K 8.94K 1.07K -25.96K
Net Change in Cash & Cash Equivalents -5.04M -13.03M 32.74M 9.51M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ATRS Antares Pharma Inc

Chart of ATRS

Analysts Ratings for ATRS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

ATRS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs